肠毒素大肠杆菌CS3定居因子抗原和融合肠毒素基因在减毒痢疾杆菌中的共表达

肠毒素和定居因子抗原 (CFAs)是肠毒素大肠杆菌 (ETEC)两种主要的致病因素。有效的ETEC疫苗应包括这两种成分。采用基因重组技术 ,将定居因子CFA/II的共有抗原成分CS3菌毛抗原和LT B/ST融合肠毒素基因克隆至以asd基因为选择标记的重组质粒上 ,与asd基因剔除的弗氏志贺氏菌Fwl0 1构成了宿主 载体平衡致死系统。结果表明 ,在无抗生素条件选择的情况下 ,该重组菌可稳定表达CS3菌毛抗原和LT B/ST融合肠毒素抗原。通过口服和鼻饲方式免疫小鼠 ,可诱生相应的血清IgG抗体 ,同时能够检测到分泌型IgA的产生 ,表明该重组菌可以有效的诱导产生粘膜免疫。     

产肠毒素大肠杆菌的热敏肠毒素B亚基(LT-B)和耐热肠毒素(ST)基因融合及其表达

采用基因重组技术构建了表达产肠毒素大肠杆菌(ETEC)的耐热肠毒素(ST)基因和热敏肠毒素B亚基(LT-B)基因融合抗原的疫苗候选株。将ST基因的5’端与LT-B基因的3’端连接,并置于同一阅读框。编码ST的基因是通过PCR从pSLM004质粒中扩增得到的,含有ST的pro序列(其编码ST前体的pro区域),并应用寡核苷酸定点突变技术将编码ST的第14位氨基酸残基发生突变,使ST的第14位氨基酸残基Ala突变为Leu。在所构建的结构中,于LT-B和proST之间分别插入了不同长度的氨基酸Linkers。表达的融合多肽同时具有ST和LT-B的抗原性,并保留结合GM-1神经节苷脂的能力,且无LT和ST的生物毒性。表达的融合蛋白免疫动物,能诱导产生相应的特异性抗体。     

人产肠毒素大肠杆菌ST、LT—B肠毒素基因融合的研究

将人产肠毒素大肠杆菌(ETEC),编码耐热肠毒素(ST)的基因片段与编码不耐热肠毒素B亚基(LT—B)的基因进行融合,并在此基础上进行不同数目sT基因的串联,ELJlSA检测融合基因表达蛋白产物观察到sT与LT－B之间存在着相互影响。ST的检测滴度随基因串联个数增加而逐渐升高,而LT的ELISA滴度则减弱。说明了ST可以通过基因串联提高表达产物抗原活性,这为产肠毒素大肠杆菌多价疫苗的研制提供了重要的研究基础。     

人产肠毒素大肠杆菌ST、LT—B肠毒素基因融合的研究

将人产肠毒素大肠杆菌(ETEC),编码耐热肠毒素(ST)的基因片段与编码不耐热肠毒素B亚基(LT-B)的基因进行融合,并在此基础上进行不同数目ST基因的串联,ELISA检测融合基因表达蛋白产物观察到ST与LT-B之间存在着相互影响。ST的检测滴度随基因串联个数增加而逐渐升高,而LT的ELISA滴度则减弱。说明了ST可以通过基因串联提高表达产物抗原活性,这为产肠毒素大肠杆菌多价疫苗的研制提供了重要的研究基础。     

大肠杆菌肠毒素的基因融合及其免疫原性的研究

应用重组基因工程技术,将热敏肠毒素Ｂ亚基（ＬＴ－Ｂ）基因与含有部分前体的耐热肠毒素（ｐｒｏ－ＳＴ）基因融合在一起,构建了表达ＬＴ－Ｂ／ｐｒｏ－ＳＴ融合蛋白的重组质粒．该融合蛋白不仅保持结合神经节苷脂（ＧＭ１）的能力,而且具有热敏肠毒素和耐热肠毒素的抗原性．乳鼠实验证明,融合蛋白虽然含有野生耐热肠毒素,但不具耐热肠毒素的生物毒性．腹腔免疫和鼻饲免疫均能激发产生抗ＥＴＥＣ两种肠毒素的抗体．     

肠毒素大肠杆菌定居因子CFA／I和CS6在减毒福氏志贺氏菌中的共表达

定居因子CFA／I和CS6是肠毒素大肠杆菌(ETEC)中重要的两种优势抗原,是ETEC疫苗研制的首选组分。采用基因重组技术将二者构建在asd基因为选择标记的重组质粒上,与asd基因缺失突变型减毒福氏志贺氏菌FWL01构成宿主．载体平衡致死系统,实验结果表明,重组疫苗候选株能够稳定表达CFA／I和CS6抗原,并可在菌体表面形成相应菌毛。重组菌口服免疫BALB／c小鼠后,可诱生相应的抗CFA／I和CS6的特异性血清抗体IsG和分泌型抗体sIgA．说明以志贺氏菌为载体．可以构建同时表达多个定居因子抗原的ETEC多价菌苗。     

人源产肠毒素大肠杆菌疫苗的研发进展

腹泻是全球范围内引起5岁以下幼童死亡的第二大病因,而产肠毒素大肠杆菌(ETEC)是引起腹泻的最常见病原菌,其产生的细菌定植因子(CFs)和肠毒素是关键的毒力因子。CFs介导细菌黏附宿主小肠上皮细胞并完成定植,产生热敏肠毒素(LT)和热稳定肠毒素(ST)破坏宿主上皮细胞内的体液平衡,使体液和电介质过量分泌从而导致腹泻。预防ETEC腹泻的首选方法是使用能激发宿主产生抗黏附素免疫力和抗肠毒素免疫力的疫苗,阻断ETEC黏附和定植并中和肠毒素。目前一种名为Dukoral~的霍乱疫苗因能刺激机体产生抗热敏毒素免疫,已经被一些国家批准用于短期保护和预防旅行者腹泻。新型试验性ETEC候选疫苗正在研发中,旨在提供保护期长、反应谱广的抗ETEC感染免疫保护力。本文针对疫苗研发的关键问题和研究现状作一综述,并对未来的研究作出展望。     

肠毒素大肠杆菌定居因子CFA/Ⅰ和CS6在减毒福氏志贺氏菌中的共表达

定居因子CFA/I和CS6是肠毒素大肠杆菌 (ETEC)中重要的两种优势抗原 ,是ETEC疫苗研制的首选组分。采用基因重组技术将二者构建在以asd基因为选择标记的重组质粒上 ,与asd基因缺失突变型减毒福氏志贺氏菌FWL0 1构成宿主 载体平衡致死系统。实验结果表明 ,重组疫苗候选株能够稳定表达CFA/I和CS6抗原 ,并可在菌体表面形成相应菌毛。重组菌口服免疫BALB/c小鼠后 ,可诱生相应的抗CFA/I和CS6的特异性血清抗体IgG和分泌型抗体sIgA ,说明以志贺氏菌为载体 ,可以构建同时表达多个定居因子抗原的ETEC多价菌苗     

肠毒素大肠杆菌定居因子CS6蛋白的纯化和抗体制备

将大肠杆菌E519／66A在CFA固体培养基上培养,收菌后经热水浴脱蛋白、硫酸铵分级盐析、超速离心及S-200柱纯化,获得了相对分子量约14600的高纯度CS6蛋白。用其免疫家兔,然后颈动脉采血。ELSIA法检测血清,测得效价为1：32000。Westem印迹证实CS6抗原蛋白可特异性结合抗CS6多克隆抗血清。本研究建立了分离纯化肠毒素大肠杆菌定居因子CS6抗原蛋白的有效方法;获得了高纯度的野生型定居因子抗原CS6蛋白及相应的多克隆抗血清。对于进一步研究肠毒素大肠杆菌腹泻疫苗具有重要意义。     

产肠毒素大肠杆菌亚单位疫苗3STaM(G)-K99和3STaM(S)-K99的纯化及其免疫学性质的研究

产肠毒素大肠杆菌(ETEC)是一种导致新生犊牛和仔猪腹泻的主要病原体之一.ETEC的毒力因子主要有黏附素(CFs)、不耐热性肠毒素(LT)和耐热性肠毒素(ST)三种.在前期研究中,利用PCR和酶切连接技术成功构建了两种ETEC亚单位疫苗3STaM (G)-K99和3STaM(S)-K99,且在大肠杆菌中获得高效表达.本研究利用阴离子交换层析纯化融合蛋白3STaM (G)-K99 and 3STaM(S)-K99,辅以弗氏佐剂免疫新西兰大白兔,通过Elisa分析其免疫学性质,并利用肠毒素中和实验在昆明系乳鼠中评价其激发抗STa中和抗体的能力.实验结果表明:亚单位疫苗3STaM(G)-K99 and 3STaM (S)-K99能够激发相对较高水平、可针对天然STa、ETEC和融合蛋白STa-K99的特异性抗体.其次,亚单位疫苗中STa突变体(STaM)组分的肠毒素活性显著降低,且其所激发的特异性抗体属于中和抗体,能有效抑制天然STa的肠毒素活性.亚单位疫苗3STaM (G)-K99 and 3STaM(S)-K99为研制预防ETEC感染性腹泻的多价基因工程疫苗提供了基本素材和理论指导.     

表达大肠杆菌LT-B/ST融合抗原的减毒鼠伤寒沙门氏菌株的构建

编码LT-B/ST融合抗原的基因插入pYA248载体中,构建了重组质粒pXZL66。该重组质粒转入无毒鼠伤寒沙门氏菌SR-11,ΔCya,Δcrp,Δasd菌株X4072。此无抗药性的杂合菌株X4072(pXZL66)表达的LT-B/ST融合抗原具有LT和ST抗原性而没有生物毒性,可望成为预防ETEC腹泻和相应的沙门氏菌病双价口服活疫苗候选株。     

Antigen-Specific Memory B-cell Responses to Enterotoxigenic Escherichia coli Infection in Bangladeshi Adults

Background

Multiple infections with diverse enterotoxigenic E. coli (ETEC) strains lead to broad spectrum protection against ETEC diarrhea. However, the precise mechanism of protection against ETEC infection is still unknown. Therefore, memory B cell responses and affinity maturation of antibodies to the specific ETEC antigens might be important to understand the mechanism of protection.

Methodology

In this study, we investigated the heat labile toxin B subunit (LTB) and colonization factor antigens (CFA/I and CS6) specific IgA and IgG memory B cell responses in Bangladeshi adults (n = 52) who were infected with ETEC. We also investigated the avidity of IgA and IgG antibodies that developed after infection to these antigens.

Principal Findings

Patients infected with ETEC expressing LT or LT+heat stable toxin (ST) and CFA/I group or CS6 colonization factors developed LTB, CFA/I or CS6 specific memory B cell responses at day 30 after infection. Similarly, these patients developed high avidity IgA and IgG antibodies to LTB, CFA/I or CS6 at day 7 that remained significantly elevated at day 30 when compared to the avidity of these specific antibodies at the acute stage of infection (day 2). The memory B cell responses, antibody avidity and other immune responses to CFA/I not only developed in patients infected with ETEC expressing CFA/I but also in those infected with ETEC expressing CFA/I cross-reacting epitopes. We also detected a significant positive correlation of LTB, CFA/I and CS6 specific memory B cell responses with the corresponding increase in antibody avidity.

Conclusion

This study demonstrates that natural infection with ETEC induces memory B cells and high avidity antibodies to LTB and colonization factor CFA/I and CS6 antigens that could mediate anamnestic responses on re-exposure to ETEC and may help in understanding the requirements to design an effective vaccination strategies.     

Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC)

Diarrheal illness contributes to malnutrition, stunted growth, impaired cognitive development, and high morbidity rates in children worldwide. Enterotoxigenic Escherichia coli (ETEC) is a major contributor to this diarrheal disease burden. ETEC cause disease in the small intestine by means of colonization factors and by production of a heat-labile enterotoxin (LT) and/or a small non-immunogenic heat-stable enterotoxin (ST). Overall, the majority of ETEC produce both ST and LT. LT induces secretion via an enzymatically active A-subunit (LT-A) and a pentameric, cell-binding B-subunit (LT-B). The importance of anti-LT antibodies has been demonstrated in multiple clinical and epidemiological studies, and a number of potential ETEC vaccine candidates have included LT-B as an important immunogen. However, there is limited information about the potential contribution of LT-A to development of protective immunity. In the current study, we evaluate the immune response against the A-subunit of LT as well as the A-subunit’s potential as a protective antigen when administered alone or in combination with the B-subunit of LT. We evaluated human sera from individuals challenged with a prototypic wild-type ETEC strain as well as sera from individuals living in an ETEC endemic area for the presence of anti-LT, anti-LT-A and anti-LT-B antibodies. In both cases, a significant number of individuals intentionally or endemically infected with ETEC developed antibodies against both LT subunits. In addition, animals immunized with the recombinant proteins developed robust antibody responses that were able to neutralize the enterotoxic and cytotoxic effects of native LT by blocking binding and entry into cells (anti-LT-B) or the intracellular enzymatic activity of the toxin (anti-LT-A). Moreover, antibodies to both LT subunits acted synergistically to neutralize the holotoxin when combined. Taken together, these data support the inclusion of both LT-A and LT-B in prospective vaccines against ETEC.     

Genetic Fusions of a CFA/I/II/IV MEFA (Multiepitope Fusion Antigen) and a Toxoid Fusion of Heat-Stable Toxin (STa) and Heat-Labile Toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) Retain Broad Anti-CFA and Antitoxin Antigenicity

Immunological heterogeneity has long been the major challenge in developing broadly effective vaccines to protect humans and animals against bacterial and viral infections. Enterotoxigenic Escherichia coli (ETEC) strains, the leading bacterial cause of diarrhea in humans, express at least 23 immunologically different colonization factor antigens (CFAs) and two distinct enterotoxins [heat-labile toxin (LT) and heat-stable toxin type Ib (STa or hSTa)]. ETEC strains expressing any one or two CFAs and either toxin cause diarrhea, therefore vaccines inducing broad immunity against a majority of CFAs, if not all, and both toxins are expected to be effective against ETEC. In this study, we applied the multiepitope fusion antigen (MEFA) strategy to construct ETEC antigens and examined antigens for broad anti-CFA and antitoxin immunogenicity. CFA MEFA CFA/I/II/IV [CVI 2014, 21(2):243-9], which carried epitopes of seven CFAs [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, was genetically fused to LT-STa toxoid fusion monomer 3xSTa_A14Q-dmLT or 3xSTa_N12S-dmLT [IAI 2014, 82(5):1823-32] for CFA/I/II/IV-STa_A14Q-dmLT and CFA/I/II/IV-STa_N12S-dmLT MEFAs. Mice intraperitoneally immunized with either CFA/I/II/IV-STa_-toxoid-dmLT MEFA developed antibodies specific to seven CFAs and both toxins, at levels equivalent or comparable to those induced from co-administration of the CFA/I/II/IV MEFA and toxoid fusion 3xSTa_N12S-dmLT. Moreover, induced antibodies showed in vitro adherence inhibition activities against ETEC or E. coli strains expressing these seven CFAs and neutralization activities against both toxins. These results indicated CFA/I/II/IV-STa_-toxoid-dmLT MEFA or CFA/I/II/IV MEFA combined with 3xSTa_N12S-dmLT induced broadly protective anti-CFA and antitoxin immunity, and suggested their potential application in broadly effective ETEC vaccine development. This MEFA strategy may be generally used in multivalent vaccine development.     

Shift in Phenotypic Characteristics of Enterotoxigenic Escherichia coli (ETEC) Isolated from Diarrheal Patients in Bangladesh

Background

Enterotoxigenic Escherichia coli (ETEC) is one of the most common causes of bacterial diarrhea. Over the last decade, from 1996 to 2012, changes in the virulence antigen properties of ETEC such as heat labile (LT) and heat stable (ST) toxins, colonization factors (CFs), and ‘O’-serogroups have been observed. The aim of this prospective study was to compare changes in antigenic profiles of ETEC strains isolated from a 2% surveillance system at the icddr,b hospital in Dhaka, Bangladesh between 2007–2012 and an earlier time period of 1996–1998 conducted at the same surveillance site.

Methodology

In the surveillance system every 50^th patient attending the hospital was screened for major enteric pathogens including ETEC, Vibrio cholerae, Shigella spp. and Salmonella spp. from January 2007 to December 2012.

Principal Findings

Of the 15,152 diarrheal specimens tested between 2007–2012, the overall rate of ETEC isolation was 11%; of these, 43% were LT/ST, 27% LT and 30% ST positive. Isolation rate of ST-ETEC (p<0.009) and LT/ST ETEC (p<0.011) during 2007–2012 period differed significantly compared to those seen between 1996–1998. In comparison to the 1996–1998 period, difference in CF profile of ETEC isolates during 2007–2012 was observed particularly for strains expressing CS7 (12.4%), CS14 (9.5%) and CS17 (10.0%). The predominant CF types were CS5+CS6, CFA/I, CS7, CS17, CS1+CS3, CS6 and CS14. The most common serogroups among the CF positive ETEC isolates were O115, O114, O6, O25 and O8. A strong association was found between CFs and ‘O’ serogroups i.e. between CS5+CS6 and (O115 and O126); CS7 and (O114), CFA/I and (O78 and O126), CS17 and (O8 and O167) and CS1/CS2+CS3 and (O6).

Conclusion

The analyses show a shift in prevalence of antigenic types of ETEC over the study period; the information is important in designing effective ETEC vaccines with broad protective coverage.     

Clonal relatedness of enterotoxigenic Escherichia coli (ETEC) strains expressing LT and CS17 isolated from children with diarrhoea in La Paz, Bolivia

Background

Enterotoxigenic Escherichia coli (ETEC) is a major cause of traveller''s and infantile diarrhoea in the developing world. ETEC produces two toxins, a heat-stable toxin (known as ST) and a heat-labile toxin (LT) and colonization factors that help the bacteria to attach to epithelial cells.

Methodology/Principal Findings

In this study, we characterized a subset of ETEC clinical isolates recovered from Bolivian children under 5 years of age using a combination of multilocus sequence typing (MLST) analysis, virulence typing, serotyping and antimicrobial resistance test patterns in order to determine the genetic background of ETEC strains circulating in Bolivia. We found that strains expressing the heat-labile (LT) enterotoxin and colonization factor CS17 were common and belonged to several MLST sequence types but mainly to sequence type-423 and sequence type-443 (Achtman scheme). To further study the LT/CS17 strains we analysed the nucleotide sequence of the CS17 operon and compared the structure to LT/CS17 ETEC isolates from Bangladesh. Sequence analysis confirmed that all sequence type-423 strains from Bolivia had a single nucleotide polymorphism; SNP_bol in the CS17 operon that was also found in some other MLST sequence types from Bolivia but not in strains recovered from Bangladeshi children. The dominant ETEC clone in Bolivia (sequence type-423/SNP_bol) was found to persist over multiple years and was associated with severe diarrhoea but these strains were variable with respect to antimicrobial resistance patterns.

Conclusion/Significance

The results showed that although the LT/CS17 phenotype is common among ETEC strains in Bolivia, multiple clones, as determined by unique MLST sequence types, populate this phenotype. Our data also appear to suggest that acquisition and loss of antimicrobial resistance in LT-expressing CS17 ETEC clones is more dynamic than acquisition or loss of virulence factors.     

Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes

An oral killed (non-replicating) whole-cell anti-ETEC vaccine was prepared by treating enterotoxigenic Escherichia coli strain H-10407 (ST + LT +; 078: H11: CFA/I) with a 100%-lethal amount of colicin E2. Colicin E2 is a potent DNA endonuclease which enters the target bacterial cells without disrupting cellular integrity. Thus the vaccine consists of intact cells lacking chromosomal and plasmid DNA but possessing a normal complement of antigens, including CFA/I and enterotoxin(s), unaltered by chemical- or heat-treatment. Young healthy volunteers were administered two oral doses, one month apart, of approximately 3 x 10(10) vaccine cells. Of 22 vaccinees, 17 (77.3%) showed an intestinal anti-CFA/I IgA response and 19 (86.4%) showed an increase in intestinal anti-LT IgA. Twenty of 22 (90.9%) vaccinees had antibody responses to either CFA/I, LT, or both antigens, demonstrating that colicin E2-treated CFA-positive E. coli cells are an efficient vehicle in terms of delivery of antigens to the gut immune system. We previously demonstrated protection of vaccinees against challenge with the living homologous ETEC (strain H-10407). In this study, two groups of 8 vaccinees were challenged with a diarrheagenic dose of virulent ST + LT + ETEC of heterologous serotype; one group was challenged with a CFA/I-positive 063: H- strain and the other group was challenged with a CFA/II-positive 06: H16 strain. Approximately 75% efficacy was achieved in both challenge groups. None of the 16 vaccinees who had responded to both CFA/I and LT became ill upon challenge while both of the vaccinees who had not responded to either antigen did.(ABSTRACT TRUNCATED AT 250 WORDS)     

Expression of plasmids coding for colonization factor antigen II (CFA/II) and enterotoxin production in Escherichia coli

Two plasmids transferred from enterotoxigenic Escherichia coli (ETEC) of serotype O6. H16 and biotypes A and C coded for mannose-resistant haemagglutination (MRHA) and production of heat-stable enterotoxin (ST) and heat-labile enterotoxin (LT). Both plasmids were nonautotransferring being mobilized most efficiently by the R plasmid R100-1. They were similar in their genetic properties being incompatible with each other and plasmids of the Inc group FI. The wild-type strains produced the colonization factor antigen II (CFA/II) which was made up of different coli surface antigens (CS). The biotype A strains produced CS1 and CS3 while the biotype C strains produced CS2 and CS3. These three antigens have the ability to cause MRHA. When plasmids coding for MRHA were transferred to K12 strains, the degree of haemagglutination was markedly reduced and only CS3 was produced. When both plasmids were transferred back into biotype A strains, good MRHA was restored and the strains produced CS1 and CS3. In a biotype C strain CS2 and CS3 were formed. The production of the antigens was compared by enzyme-linked immunosorbent assay (ELISA). The strains were also examined by electron microscopy where it was found that CS1 and CS2 were fimbrial antigens while CS3 was not.     

Positive regulation of colonization factor antigen I (CFA/I) production by enterotoxigenic Escherichia coli producing the colonization factors CS5, CS6, CS7, CS17, PCFO9, PCFO159:H4 and PCFO166

Entertoxigenic Escherichia coli (ETEC) strains of nineteen serogroups which produced colonization factors (coli-surface-associated antigens CS5, CS6, CS7 and CS17, colonization factor antigen CFA/III and putative colonization factors PCFO159:H4, PCFO166 and PCFO9) were tested for hybridization with a DNA probe containing the cfaD sequence that regulates expression of CFA/I. Strong colony hybridization, similar to that with the CFA/I-positive control strain H10407, occurred with ETEC strains of serogroups O27, O159 and O169 which produced CS6 antigen, and with all the strains which produced PCFO166 fimbriae. Weak colony hybridization, compared to the control strain, was found with ETEC producing CS5 fimbriae with CS6 antigen, CFA/III fimbriae with CS6 antigen, CS7 fimbriae or PCFO159:H4 fimbriae. CS6-antigen-positive strains of serogroups O79, O89 and O148 and all the CS17-antigen-positive and PCFO9-fimbriae-positive strains were negative in colony hybridization tests with the cfaD probe. Plasmid DNA of nine ETEC strains and their colonization-factor-negative derivatives was tested for hybridization with the cfaD probe and with ST and LT oligonucleotide probes. The sequences that hybridized with the cfaD probe were on the plasmids which coded for enterotoxin production. Fifteen strains were transformed with NTP513, a recombinant plasmid which contains the CFA/I region 1 fimbrial subunit operon but lacks a functional cfaD sequence, in order to determine whether DNA in any of these strains could substitute for the cfaD sequence in the regulation of production of CFA/I fimbriae.(ABSTRACT TRUNCATED AT 250 WORDS)     

表达幽门螺杆菌黏附素保守区的减毒鼠伤寒沙门氏菌株的构建

为构建表达幽门螺杆菌（Hp）黏附素保守区（AB）的无抗性减毒鼠伤寒沙门氏菌疫苗,采用缺失腺苷酸环化酶基因（Δcya）、环腺苷酸受体蛋白基因（Δcrp）以及天冬氨酸β-半醛脱氢酶基因（Δasd）的鼠伤寒沙门菌（X4072）作为宿主,将编码AB的基因插入Asd⁺的组成型表达载体pYA248,通过两次转化引入宿主菌,构建了表达AB基因平衡致死的减毒鼠伤寒沙门重组菌X4072（pYA248-AB）,采用桥联法ELISA测定X4072（pYA248-AB）培养上清液和裂解上清液中AB的抗原性,参照Meacock叙述的方法及重组菌生长曲线的测定来确定重组菌株的稳定性,通过C57BL/6小鼠口服测定半致死量来确定重组菌的安全性。成功构建了表达AB的减毒鼠伤寒沙门菌重组菌株S.typhimurium X4072(pYA248-AB),桥联法ELISA测定表明重组菌X4072（pYA248-AB）培养上清中AB的含量高于菌体裂解液,重组菌pYA248-AB在没有选择压力的情况下培养100代,随机挑选的重组菌全部都能生长,且在ELISA测定AB抗原时均显阳性。重组菌的生长曲线测定表明,X4072（pYA248）和X4072（pYA248-AB）的生长状态基本一致;口服重组菌株X4072(pYA248-AB)1.0×10¹⁰cfu.30d后,C57BL/6存活率仍为100%。成功构建了表达AB的无抗性的减毒鼠伤寒沙门菌疫苗X4072（pYA248-AB）,体外实验表明重组质粒是稳定的,动物实验证明重组菌株是安全的;为防治幽门螺杆菌感染提供了口服活菌疫苗候选株。